Home / Content / B2B Connect / Pharma / Zydus Cadila receives US FDA approval for cholestyramine suspension

Zydus Cadila receives US FDA approval for cholestyramine suspension

It is indicated as an adjunctive therapy for reduction of elevated serum cholesterol in patients

Pfizer stops production of Corex cough syrup

premium

Last Updated : May 02 2017 | 1:26 PM IST

Zydus Cadila has received the final approval from the US Food & Drug Administration (FDA) to market cholestyramine for oral suspension USP (4 gm per scoopful).

It is indicated as an adjunctive therapy to the diet for the reduction of elevated serum cholesterol in patients with primary hypercholesteolemia - elevated low density lipoprotein (LDL) cholesterol - who do not respond adequately to diet. Cholestyramine will be produced at the group’s formulations manufacturing facility at Baddi.

The group now has more than 110 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.